Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Pfizer (NY:PFE)

22.97 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, May 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Forecasting The Future: 6 Analyst Projections For Pfizer
Via Benzinga
Upcoming Pfizer Earnings Call Might Be Focused On Tariffs, Policy Risks And Obesity Pipeline
Pfizer Inc (NYSE:PFE) is scheduled to release its first quarter 2025 earnings on 29 April. 
Via Benzinga
Topics Earnings
Exposures Financial
How To Put $100 In Your Retirement Fund Each Month With Pfizer Stock
Via Benzinga
Topics Retirement
Exposures Pension
Hertz Global And Webull Stocks Are Among Top Mid-Cap Gainers Last Week (Apr 14-Apr 18): Are The Others In Your Portfolio?
Top mid-cap performers last week: Webull Corp, Hertz Global, Metsera Inc, Vista Energy, Certara Inc, Sibanye-Stillwater, Banco Macro, Grupo Financiero Galicia, Banco BBVA Argentina, Recursion... 
Via Benzinga
3 Ultra-High-Yield Dividend Stocks to Buy Right Now That Are Dirt Cheap
Via The Motley Fool
Topics Economy Energy
Exposures Climate Economy Fossil Fuels
A Once-in-a-Decade Opportunity: 3 Magnificent Stocks Down Between 40% and 73% to Buy Right Now
Via The Motley Fool
3 Magnificent Stocks to Buy That Are Near 52-Week Lows
Via The Motley Fool
Topics Economy Government
Exposures COVID-19 Economy Political
Pfizer Abandons Its Leading Weight Loss Candidate. Should You Sell the Stock?
Via The Motley Fool
Where Will Eli Lilly Be in 5 Years?
Via The Motley Fool
3 Magnificent S&P 500 Dividend Stocks Down 11% to 63% to Buy and Hold Forever
As tough as it may be to do right now, this is a great time to hold your nose and dive in while yields are as high as they are. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Thursday's session: most active stock in the S&P500 index
Looking for the most active stocks in the S&P500 index on Thursday? Dive into today's session and discover the stocks that are dominating the trading activity and setting the pace for the market. 
Via Chartmill
US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years
CDC panel expands Pfizer and GSK RSV vaccine use to high-risk adults 50–59, building on earlier recommendations for older populations. 
Via Benzinga
Lilly's Diabetes Pill Clears Major Trial, Analyst Points To Global Potential
Eli Lilly reported positive results from Phase 3 ACHIEVE-1 trial of orforglipron for type 2 diabetes, meeting primary endpoint of A1C reduction. Analysts see potential for sales of $10 billion by... 
Via Benzinga
Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide
Eli Lilly has a plan to dominate the GLP-1 weight loss drug market -- and it's succeeding. 
Via The Motley Fool
Mark Cuban Says This Trump Healthcare Order 'Could Save Hundreds Of Billions'
Billionaire entrepreneur Mark Cuban has expressed support for President Donald Trump's 2025 healthcare executive order, emphasizing its potential to reform the role of Pharmacy Benefit Managers (PBMs)... 
Via Benzinga
Topics Government
Exposures Political
2 of Wall Street’s Favorite Stocks with Competitive Advantages and 1 to Be Wary Of
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
Eli Lilly Stock Rockets On Weight-Loss Pill Progress
Eli Lilly's pill-form weight loss drug cansdidate cleared one of several Phase III hurdles. 
Via Investor's Business Daily
Topics Government
Exposures Political Product Safety
Eli Lilly's Oral GLP-1 Drug Orforglipron Hits Phase 3 Goals In Diabetes Trial, Stock Soars
Eli Lilly's oral GLP-1 drug orforglipron met key Phase 3 goals in type 2 diabetes, lowering A1C and weight with a favorable safety profile. 
Via Benzinga
Trump Tariff Plunge: 3 Phenomenal Stocks to Buy at Bargain Prices Right Now
Tariff uncertainty has created an ideal opportunity for long-term investors to pounce. 
Via The Motley Fool
Topics Economy Government Stocks
Exposures Economy Interest Rates Political
Mr. Ethan Billings recommends paying close attention to biotech stocks
Via Binary News Network
ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease
From Pfizer Inc.
Via Business Wire
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction
Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating... 
Via Benzinga
Topics Government
Exposures Political
BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc Disease
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc Disease
By Meg Flippin Benzinga 
Via TheNewswire.com
Exposures Product Safety
Will Pfizer Approach Viking Therapeutics With A Buyout Proposa
Investors are running into Viking Therapeutics this week after an incident of drug-induced liver injury pushed Pfizer into terminating the development of its weight-loss pill. 
Via Talk Markets
Topics Stocks / Equities
Why Pfizer Stock Topped the Market on Tuesday
Via The Motley Fool
Exposures COVID-19
Most active S&P500 stocks in Tuesday's session
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the most active S&P500 stocks in today's session. 
Via Chartmill
Novavax Covid Vaccine Shows Milder Side Effects Than Pfizer-BioNTech's Shot: Study
Novavax updated Covid vaccine showed fewer and milder side effects than Pfizer-BioNTech's in a Utah study. 
Via Benzinga
Exposures COVID-19
Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill?
Via The Motley Fool
Wall Street Sees Pfizer's Weight-Loss Pill Exit As A Win For 2 Smaller Biotech Firms: Retail Turns Bullish
Investors are now considering the possibility of Pfizer acquiring either of these companies as it looks for external candidates. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.